Literature DB >> 2836313

Hepatitis A in young Norwegian drug addicts and prison inmates.

E Holter1, J C Siebke.   

Abstract

Prevalence of antibodies against hepatitis A (anti-HAV) among young Norwegian drug addicts in 1983 and the relative incidence of specific IgM against hepatitis A (anti-HAV IgM) during the years 1973-1983 have been studied. The survey is based on 1,689 serum samples from 561 persons submitted to hepatitis B screening or clinical hepatitis testing. The prevalence of anti-HAV in such groups was 43% in 1983 versus about 5% in corresponding age groups in the general population and 1% in the Norwegian U.N. soldiers in Lebanon. Presence of anti-HAV clearly correlated with presence of hepatitis B markers. Considerable fluctuations in the incidence of hepatitis A seemed to occur among drug addicts, with pronounced epidemic peaks in 1975 and 1979, coinciding with epidemics in Malmö, Sweden. Though the incidence varied, hepatitis A may have persisted among addicts for some years after 1979 in a semi-endemic manner. Although relatively young, most of them seem to have been in the milieu for some time before catching the infection. Drug addicts seem to be a target group for future hepatitis A vaccination programs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836313     DOI: 10.1007/BF01644310

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Increased occurrence of hepatitis A with cyclic outbreaks among drug addicts in a Swedish community.

Authors:  A Widell; B G Hansson; T Moestrup; E Nordenfelt
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

2.  Viral hepatitis among parenteral drug addicts attending a Danish addiction clinic.

Authors:  F Scheutz; P Skinhøj; I Mark
Journal:  Scand J Infect Dis       Date:  1983

3.  Rectum carried drugs may spread hepatitis A among drug addicts.

Authors:  T Sundkvist; B Johansson; A Widell
Journal:  Scand J Infect Dis       Date:  1985

4.  Prevalence of hepatitis A antibodies in a normal population and some selected groups of patients in Norway.

Authors:  J C Siebke; M Degré; S Ritland; S C Enger
Journal:  Am J Epidemiol       Date:  1982-02       Impact factor: 4.897

5.  Posttransfusion hepatitis type A.

Authors:  F B Hollinger; N C Khan; P E Oefinger; D H Yawn; A C Schmulen; G R Dreesman; J L Melnick
Journal:  JAMA       Date:  1983-11-04       Impact factor: 56.272

6.  Prevalence of viral hepatitis in the staff in Norwegian anaesthesiology units.

Authors:  J C Siebke; M Degré
Journal:  Acta Anaesthesiol Scand       Date:  1984-10       Impact factor: 2.105

  6 in total
  4 in total

1.  Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak.

Authors:  Y J Hutin; B P Bell; K L Marshall; C P Schaben; M Dart; M P Quinlisk; C N Shapiro
Journal:  Am J Public Health       Date:  1999-06       Impact factor: 9.308

Review 2.  Hepatitis A: old and new.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

3.  Hepatitis A in Western Austria--the epidemiological situation before the introduction of active immunisation.

Authors:  W M Prodinger; C Larcher; B M Sölder; D Geissler; M P Dierich
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

Review 4.  New developments in hepatitis A control.

Authors:  L Yuan
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.